GSK expands skin care portfolio
This article was originally published in The Tan Sheet
Executive Summary
Consumer Healthcare division acquires five Rx topical dermatological products from Elan Pharmaceuticals, GSK announces Dec. 23. Firm will market Temovate, Emgel, Aclovate, Cutivate and Oxistat beginning Jan. 1, noting brands "are an excellent fit with" GSK's current OTC dermatology products Oxy (for acne)and Abreva (for cold sores). Firm expects "medical marketing expertise" gained from co-marketing Rx products such as Bactroban will add to success of acquisition. According to GSK, Elan reported the five products generated sales of $62 mil. in 2001...